Hyderabad: CCMB, Arya Vaidya Sala join hands in fight against Covid
A 118-year-old charitable institution, AVS has been engaged in the practice and propagation of Ayurveda, manufacturing more than 500 formulations
Hyderabad: Hyderabad based CSIR-Centre for Cellular and Molecular Biology (CCMB), on Friday, tied up with Arya Vaidya Sala (AVS), Kottakkal, Kerala to check for the efficacy of Ayurvedic formulations in the fight against the coronavirus SARS-CoV-2.
A 118-year-old charitable institution, AVS has been engaged in the practice and propagation of Ayurveda, manufacturing more than 500 formulations. In this partnership, AVS will provide standardised Ayurveda formulations and CCMB will test them on the lab-grown coronavirus strains and check for their anti-viral efficacy.
CCMB Director, Dr. Rakesh Mishra pointed out that while India possessed a lot of ancient wisdom, it has lacked defined regulatory protocols for testing the efficacy of formulations that were based on the ancient texts. “In the ongoing fight against the coronavirus, it has become imperative to rigorously test the different treatment possibilities before they are used by the public,” he said.
CCMB has established an efficacy testing facility for drugs and devices by using the lab-grown coronavirus, which could be used for ayurvedic formulations too. “If it yields tangible results, the project will lead to a major progress in the pharmaceutical industry in India”, said Dr.Mishra.
Dr. C T. Sulaiman, Senior Scientist, AVS, said, “AVS is joining hands with CCMB with the clear objective of attempting to validate classical knowledge of Ayurveda with the aid of modern science. We are hopeful that findings of this study will yield useful therapeutic support in the current situation. The chemical evaluation of the selected formulations showed presence of potent molecules, and they will be investigated further.”
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
